fool.com · 29 jun

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year

Thomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share. This transaction reduced his direct Common Stock holdings by 51.33%, leaving 177,461 shares directly held after the sale.

seekingalpha.com · 8 jun

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

globenewswire.com · 27 may

Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June

CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in two upcoming fireside chats in June: 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:45 p.m.

fool.com · 22 may

Is Relay Therapeutics a Buy After Promising Trial Results?

Relay had its initial public offering in 2020. The company's lead therapy is being tested for the treatment of vascular disorders and cancers.

globenewswire.com · 20 may

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.

globenewswire.com · 20 may

Relay Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, announced today the pricing of an underwritten public offering of 22,916,667 shares of its common stock at a public offering price of $12.00 per share. Relay Therapeutics also granted the underwriters a 30-day option to purchase up to an additional 3,437,500 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $275 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Relay Therapeutics.

fool.com · 20 may

Why Relay Therapeutics Stock Popped on Wednesday

This was aided by a pair of bullish analyst updates. The two pundits raised their price targets and maintained their buy ratings.

seekingalpha.com · 20 may

Relay Therapeutics: Zovegalisib Is Becoming A Platform In Disguise

Relay Therapeutics is undervalued as the market overlooks its potential to build a multi-indication PI3Kα inhibitor franchise beyond breast cancer. Zovegalisib's Breakthrough Therapy designation and strong Phase 3 data support its differentiated tolerability and efficacy profile, targeting both oncology and vascular anomalies. RLAY's $642M cash position, recent ATM raise, and cost controls provide runway into 2029, enabling pivotal trials and pipeline expansion without near-term financing risk.